QBQing Bi

Qing Bi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qing Bi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Jiandong Zhang

    Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, 100020, China, ccmu.edu.cn

    3 shared publications
  • Jiyue Wu

    Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, 100020, China, ccmu.edu.cn

    3 shared publications
  • Wei Wang

    Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

    3 shared publications
  • Xuemeng Qiu

    Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, 100020, China, ccmu.edu.cn

    3 shared publications
  • Yifei Zhang

    Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, 100020, China, ccmu.edu.cn

    2 shared publications
  • Yuqing Li

    Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing, 100020, China, ccmu.edu.cn

    2 shared publications

Latest Publications

  • Open Access

    Immune Infiltration‐Related Genes as Potential Biomarkers and Predicted Targets for Renal Allograft Delayed Graft Function and Survival Outcome: An Integrated Machine Learning Approach and Drugs Analysis

    by Yifei Zhang, Yuqing Li, Xuemeng Qiu, Jiyue Wu, Qing Bi, Peng Cao, Jiandong Zhang, Wei Wang

    Background: Ischemia‐reperfusion injury (IRI) significantly impacts post‐kidney transplantation (KTx), leading to delayed graft function (DGF) and potential graft loss. Current biomarkers and therapies for DGF and graft survival are inadequate. Immune cell infiltration after renal IRI is crucial in driving inflammation and injury. Methods: To address this, this study utilized microarray and RNA‐seq datasets from the Gene Expression Omnibus (GEO) database to identify differentially expressed immune infiltration‐related genes (DE‐IRGs) in IRI patients. Machine learning (ML) algorithms pinpointed hub DE‐IRGs, aiding in predictive model development and classification of post‐KTx IRI samples into clusters and risk groups. Regulatory networks incorporating transcription factors (TFs) and microRNAs (miRNAs) were constructed using NetworkAnalyst 3.0, and predicted compounds/commonly used immunosuppressants were explored via Enrichr and molecular docking simulations. Results: Analysis revealed 47 DE‐IRGs, with hub genes (adrenomedullin [ADM], Serpin Family H Member 1 [SERPINH1], Solute carrier family 2 member 3 [SLC2A3], BCL‐2‐associated athanogene 3 [BAG3], NFKB inhibitor alpha [NFKBIA], Kruppel‐like factor 6 [KLF6], and CCAAT/enhancer‐binding protein delta [CEBPD]) linked to DGF and, in part, graft survival. Predictive models showed robust performance based on internal validation, with the DGF models achieving AUCs of 0.832 and 0.975 and graft survival models showing AUCs of 0.773, 0.742, and 0.757 for 1, 2, and 3 years, respectively. Higher immune cell infiltration correlated with adverse outcomes in cluster A or high‐risk groups. Key immune cells associated with DGF included activated CD8 T cells, activated dendritic cells (DCs), and effector memory CD4 T cells. Core regulatory TFs and miRNAs were identified, along with four core predicted compounds: acetaminophen, estradiol, valproic acid, and berbamine (which require further pharmacological validation), and three common immunosuppressants: cyclosporin A, mycophenolate mofetil (MMF), and tacrolimus. Conclusions: Our study identified potential hub genes most associated with immune cells during the post‐KTx IRI process, shedding light on the intricate interplay between genes, immune cells, and KTx outcomes.

  • Open Access

    Diverse regulated cell death patterns and immune traits in kidney allograft with fibrosis: a prediction of renal allograft failure based on machine learning, single-nucleus RNA sequencing and molecular docking

    by Yuqing Li, Jiandong Zhang, Xuemeng Qiu, Yifei Zhang, Jiyue Wu, Qing Bi, Zejia Sun, Wei Wang

    Methods and Results: Microarray transcriptome profiling and single-nuclei sequencing data of post-transplant fibrotic and normal grafts were obtained and used to identify RCD-related differentially expressed genes. The enrichment activity of nine RCD modalities in tissue and cells was examined using single-sample gene set enrichment analysis, and their relations with immune infiltration in renal allograft samples were also assessed. Parenchymal and non-parenchymal cells displayed heterogeneity in RCD activation. Additionally, cell–cell communication analysis was also conducted in fibrotic samples. Subsequently, weighted gene co-expression network analysis and seven machine learning algorithms were employed to identify RCD-related hub genes for renal fibrosis. A 9-gene signature, termed RCD risk score (RCDI), was constructed using the least absolute shrinkage and selection operator and multivariate Cox regression algorithms. This signature showed robust accuracy in predicting 1-, 2-, and 3-year allograft survival status (area under the curve for 1-, 2-, and 3-year were 0.900, 0.877, 0.858, respectively). Immune infiltration analysis showed a strong correlation with RCDI and the nine model genes. Finally, molecular docking simulation suggested rapamycin, tacrolimus and mycophenolate mofetil exhibit strong interactions with core RCD-related receptors. Conclusions: In summary, this study explored the activation of nine RCD pathways and their relationships with immune traits, identified potential RCD-related hub genes associated with renal fibrosis, and highlighted potential therapeutic targets for renal allograft fibrosis.


  • Open Access

    Tumor-Associated Inflammation: The Tumor-Promoting Immunity in the Early Stages of Tumorigenesis

    by Qing Bi, Ji-Yue Wu, Xue-Meng Qiu, Jian-Dong Zhang, Ze-Jia Sun, Wei Wang

    Tumorigenesis is a multistage progressive oncogenic process caused by alterations in the structure and expression level of multiple genes. Normal cells are continuously endowed with new capabilities in this evolution, leading to subsequent tumor formation. Immune cells are the most important components of inflammation, which is closely associated with tumorigenesis. There is a broad consensus in cancer research that inflammation and immune response facilitate tumor progression, infiltration, and metastasis via different mechanisms; however, their protumor effects are equally important in tumorigenesis at earlier stages. Previous studies have demonstrated that during the early stages of tumorigenesis, certain immune cells can promote the formation and proliferation of premalignant cells by inducing DNA damage and repair inhibition, releasing trophic/supporting signals, promoting immune escape, and activating inflammasomes, as well as enhance the characteristics of cancer stem cells. In this review, we focus on the potential mechanisms by which immune cells can promote tumor initiation and promotion in the early stages of tumorigenesis; furthermore, we discuss the interaction of the inflammatory environment and protumor immune cells with premalignant cells and cancer stem cells, as well as the possibility of early intervention in tumor formation by targeting these cellular mechanisms.